Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in the USA / NCT07270783
Active, not recruiting Phase 1

Healthy Volunteer Study

NCT07270783 · tracked via the Priya Life Science USA tracker
Sponsor
InventisBio Co., Ltd
Phase
Phase 1
Started
2025-12-04
Last updated
2026-10-13

Condition(s) studied

Healthy Volunteer

Investigational drug(s) / intervention(s)

D-2570 →Placebo

D-2570: D-2570

Placebo: Placebo

Study summary

Double Blinded Healthy Volunteer study evaluating D-2570 against placebo in various doses.

Eligibility

Sex
ALL
Min age
18 Years
Max age
55 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Healthy volunteer subjects meeting eligibility criteria Exclusion Criteria: * Subjects with ongoing or history of disease or co-morbidities as assessed by Principal Investigator which would make them ineligible for the study * Subjects with a history of drug and alcohol abuse * Subjects taking medications, over the counter or herbal remedies

Primary outcome measure(s)

  • Incidence of adverse events — From Informed Consent through study completion, an average of 48 days
    Incidence of adverse events
  • Result of Pharmacokinetic endpoint — From Randomization through study completion, an average of 20 days
    Tmax
  • Result of Pharmacokinetic endpoint — From Randomization through study completion, an average of 20 days
    Cmax
  • Result of Pharmacokinetic endpoint — From Randomization through study completion, an average of 20 days
    t1/2
  • Result of Pharmacokinetic endpoint — From Randomization through study completion, an average of 20 days
    MRT
  • Result of Pharmacokinetic endpoint — From Randomization through study completion, an average of 20 days.
    AUC0-∞
  • Result of Pharmacokinetic endpoint — From Randomization through study completion, an average of 20 days
    AUC0-t
  • Result of Pharmacokinetic endpoint — From Randomization through study completion, an average of 20 days
    CL/F
  • Result of Pharmacokinetic endpoint — From Randomization through study completion, an average of 20 days
    Vz/F

Trial sites (1)

FacilityCityRegionStatus
Pharmaron Baltimore Maryland

More InventisBio Co., Ltd trials in the USA

A Study to Evaluate D-2570 in Participants With Moderate to Severe Plaque Psoriasis Recruiting

Other trials for the same condition

A Study to Assess How Intravenous and Subcutaneous Administrations of Risankizumab Moves Through the Body of Healthy Adult Participants Recruiting
A Study to Learn About the Safety of BIIB142 and How it is Processed in the Body of Healthy Adult Participants Aged 18 to 55 Years Old Recruiting
A Study to Learn How Fluconazole, Carbamazepine and Itraconazole Affect How the Body Processes ASP3082 in Healthy Adults Active, not recruiting
Study to Evaluate Safety and Activity of Inhaled TRL1068 in Healthy Volunteers Starting soon
A Study to Evaluate How the Study Drug Moves Through the Body, Adverse Events, and How the Body Tolerates ABBV-547 Injections Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07270783 on ClinicalTrials.gov ↗ ← All trials in the USA